 An MK-2461 analog was therefore tested against a variety of c-Met mutants but proved to be no less potent against them.This gives the molecule a big advantage as a treatment for tumours caused by c-Met dysregulation.MK-2461 was undergoing phase I dose escalation trials in 2010.